Novel intermittent electrocoagulation technique reduces post-endoscopic submucosal dissection electrocoagulation syndrome in colorectal neoplasms

Table 2 Endoscopic procedure-related and lesion characteristics between groups, mean ± SD/n (%)/median (interquartile range)

	I-ESD (n = 94)	C-ESD (n = 105)	P value
Size, mm	20.2 ± 9.4	20.4 ± 7.4	0.1762
Procedural time, minute	42.0 (30.0-60.0)	49.0 (35.0-62.0)	0.0572
Procedural speed, mm2/minute	4.9 (2.9-7.6)	4.6 (3.0-7.4)	0.6472
En bloc resection	93 (98.9)	104 (99.0)	1.0001
R0 resection	87 (92.6)	98 (93.3)	0.830
Histopathology			0.8881
Serrated lesion	23 (24.5)	29 (27.6)
Adenoma	54 (57.4)	54 (51.4)
Carcinoma
Tis	1 (1.1)	2 (1.9)
SM1	0	1 (1.0)
Others	16 (17.0)	19 (18.1)
Adverse events			0.031
Bleeding	2 (2.1)	6 (5.7)
Perforation	0	0
PECS	8 (8.5)	20 (19.0)	0.033
Abdominal pain (NRS ≥ 4)	9 (9.6)	24 (22.9)	0.012
Postoperative max temperature, °C	37.0 (36.9-37.2)	37.1 (37.0-37.4)	0.0032
			0.013
≥ 37.8	6 (6.4)	19 (18.1)
< 37.8	88 (93.6)	86 (81.9)
WBC ≥ 10000/μL	2 (2.1)	8 (7.6)	0.1061
CRP ≥ 1 mg/dL	4 (4.3)	15 (14.3)	0.016
Intraoperative adverse event	0	0
Muscle layer exposure	6 (6.4)	6 (5.7)	0.843
NPO duration, days	1 (1-1)	1 (1-1)	0.2362
Length of hospital stay, days	5 (4-6)	5 (4-7)	0.4572

¹Fisher’s exact test.

²Wilcoxon rank-sum test.

The P value for “adverse events” represents the overall comparison of all adverse events, including bleeding, perforation, post-endoscopic submucosal dissection electrocoagulation syndrome, and other events. Others including neuroendocrine tumors, lipomas, lymphangiomas, and schwannomas. I-ESD: Intermittent electrocoagulation; C-ESD: Conventional continuous electrocoagulation; Tis: Tumor in situ; SM1: Submucosal invasion depth level 1; PECS: Post-endoscopic submucosal dissection electrocoagulation syndrome; NRS: Numerical rating scale; WBC: White blood cell; CRP: C-reactive protein; NPO: Nil per os.